{"filings":[{"id":92589,"accession_number":"0001104659-26-055241","cik":1393434,"company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ocular Therapeutix Q1 net loss $88.6M; cash $666.7M; AXPAXLI NDA on track with SOL-1 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $88.6M ($0.40 per share) vs $64.1M ($0.38) in Q1 2025; revenue $10.8M, up 0.8%.","Cash $666.7M as of March 31, 2026; runway into 2028 excluding full AXPAXLI commercialization costs.","AXPAXLI NDA for wet AMD on track based on SOL-1 Week 52 data; subject to FDA discussions; 505(b)(2) pathway may shorten review.","SOL-1 positive: superior visual outcomes (74.1% maintained vision at Week 36 vs 55.8% aflibercept); p=0.0006 primary endpoint.","SOL-R non-inferiority trial on track for topline 1Q 2027; HELIOS-3 ongoing; Investor Day June 17, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":10785000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1937930532.7830918,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103538,"accession_number":"0001104659-26-021541","cik":1393434,"company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Ocular Therapeutix makes slides with SOL-1 Phase 3 results for AXPAXLI in wet AMD available at Macula Society","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Slides from 49th Macula Society Annual Meeting on Feb 27, 2026 posted on investor website.","Presentation covers detailed results from SOL-1 Phase 3 superiority trial of AXPAXLI (OTX-TKI).","AXPAXLI is being developed for treatment of wet age-related macular degeneration (wet AMD).","Filing does not disclose the actual trial outcomes or numerical results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1937930532.7830918,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103537,"accession_number":"0001104659-26-010633","cik":1393434,"company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ocular Therapeutix Q4 net loss $0.29/shr; SOL-1 data readout at Macula Society Feb 25-28","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net revenue $13.3M, down 22.4% YoY; full year $52.0M, down 18.5%.","Net loss Q4 $64.7M ($0.29/shr), full year $265.9M ($1.42/shr); R&D spend rose to $50.8M.","SOL-1 Phase 3 wet AMD superiority data to be presented at Macula Society meeting Feb 25-28, 2026.","Plans to submit NDA for AXPAXLI in wet AMD based on SOL-1, pending positive results and FDA interactions.","Cash $737.1M as of Dec 31, 2025; raised $475M in Sep 2025 equity offering; runway into 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":51951000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1937930532.7830918,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103536,"accession_number":"0001104659-26-006015","cik":1393434,"company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Ocular Therapeutix CFO Donald Notman takes temporary medical leave; Jason Robins appointed interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective Jan 20, 2026, CFO/COO Donald Notman on temporary leave; Jason Robins named interim CFO and principal financial/accounting officer.","Robins granted option to purchase 33,000 shares at $11.45/share, vesting monthly over four years.","Robins, age 49, was SVP Finance since Jan 2025; previously VP Finance at Fusion Pharmaceuticals (acquired by AstraZeneca).","No family relationships or related party transactions with Robins; standard indemnification agreement executed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1937930532.7830918,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119793,"accession_number":"0001104659-25-122564","cik":1393434,"company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ocular Therapeutix enters quiet period for SOL-1 Phase 3 trial; data on track Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quiet period for SOL-1 Phase 3 trial of AXPAXLI (wet AMD) begins December 20, 2025.","Next investor communication expected early February 2026 with Q4/FY2025 results.","SOL-1 data remain on track for release in the first quarter of 2026.","No financial results or clinical data provided; no exhibits attached."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1937930532.7830918,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119792,"accession_number":"0001104659-25-118940","cik":1393434,"company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ocular Therapeutix to submit AXPAXLI NDA based on SOL-1 year 1 data after FDA flexibility signal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA signals may allow single pivotal trial for AXPAXLI in wet AMD, changing prior two-trial requirement.","Ocular Therapeutix now plans to submit NDA based on year 1 data from SOL-1 Phase 3 trial.","Top-line year 1 data from SOL-1 expected in Q1 2026.","Company will engage with FDA on regulatory pathway for AXPAXLI."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1937930532.7830918,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119791,"accession_number":"0001104659-25-105914","cik":1393434,"company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ocular Therapeutix Q3 net loss $69.4M; SOL-R hits 555 subjects; cash ~$790M with offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $(69.4)M ($0.38 loss per share) vs $(36.5)M loss in Q3 2024; revenue $14.5M, down 5.8% YoY.","SOL-R registrational trial in wet AMD achieved target randomization of 555 subjects; topline data on track for 1H 2027.","Cash balance $344.8M at Sep 30, plus ~$445M net proceeds from Oct equity offering providing runway into 2028.","HELIOS Phase 3 program for AXPAXLI in NPDR to start imminently using novel DRSS endpoint.","R&D expenses rose to $52.4M from $37.1M due to clinical trial costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":38701000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1937930532.7830918,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136359,"accession_number":"0001104659-25-094758","cik":1393434,"company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Ocular Therapeutix prices $475M common stock offering at $12.53/share to fund AXPAXLI trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 37,909,018 shares priced at $12.53 each for gross proceeds ~$475M; net proceeds ~$445.9M.","Net proceeds plus existing cash expected to fund operations into 2028, excluding full AXPAXLI commercial launch costs.","Funds to support AXPAXLI open-label extension in wet AMD, Phase 3 trials in NPDR, and manufacturing scale-up.","Offering expected to close Oct 1, 2025; BofA Securities, TD Cowen, Piper Sandler & Co. acting as joint book-runners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1937930532.7830918,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136358,"accession_number":"0001104659-25-094724","cik":1393434,"company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ocular Therapeutix updates AXPAXLI trials: SOL-1 topline Q1 2026, SOL-R H1 2027; initiates NPDR Phase 3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SOL-1 Phase 3 wet AMD trial topline results expected Q1 2026; retention >95%, rescue events >95% meet criteria, no new safety signals.","SOL-R Phase 3 wet AMD trial enrollment completed, randomization ongoing; topline results expected H1 2027.","Plans to initiate SOL-X long-term extension trial following SOL-1/SOL-R; subjects receive AXPAXLI every 24 weeks for 3 years.","Initiates Phase 3 NPDR program with HELIOS-2 (432 subjects) and HELIOS-3 (930 subjects); FDA SPA agreement for HELIOS-2 design.","Received notice of allowance from USPTO for patent covering treating ocular diseases with AXPAXLI; expiration expected 2044."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1937930532.7830918,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136357,"accession_number":"0001104659-25-073909","cik":1393434,"company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ocular Therapeutix Q2 revenue falls 18% to $13.5M; net loss $67.8M; SOL-1 data Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net revenue $13.5M, down 18% YoY; DEXTENZA unit sales up 5% but net revenue pressured by reimbursement challenges.","Net loss $67.8M ($0.39/share) vs $43.8M ($0.26) YoY; R&D spend $51.1M (up 77%) driven by SOL trial costs.","Cash $391.1M; raised ~$97M via ATM in June; runway into 2028, well beyond SOL-1 and SOL-R data.","SOL-1 Phase 3 wet AMD top-line data on track for Q1 2026; SOL-R data expected 1H 2027 with streamlined rescue criteria.","Received FDA feedback on NPDR/DME program; Investor Day Sept 30 in NYC to detail strategy and commercial outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":24156000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1937930532.7830918,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153489,"accession_number":"0001104659-25-058525","cik":1393434,"company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.02","5.03","5.07","8.01","9.01"],"status":"ready","headline":"SOL-R enrollment complete; shareholders approve 8.75M share increase and CEO award","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SOL-R Phase 3 trial for AXPAXLI (wet AMD) completed enrollment on May 31, 2025; target randomization of at least 555 subjects.","Stockholders approved Amendment No. 4 increasing 2021 Stock Incentive Plan shares by 8,750,000 shares.","Stockholders approved Amended and Restated ESPP increasing shares by 2,000,000 and removing evergreen provision.","CEO Dr. Dugel granted performance stock option award for up to 2,750,000 shares at $7.44/share, vesting on stock price hurdles.","Certificate of Amendment filed to provide officer exculpation (limitation of liability) per Delaware law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1937930532.7830918,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153488,"accession_number":"0001104659-25-044349","cik":1393434,"company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ocular Therapeutix Q1 net revenue down 27.6% to $10.7M; cash $349.7M, runway to 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $64.1M ($0.38 per share) vs. $64.8M ($0.49) in Q1 2024; R&D expenses doubled to $42.9M on wet AMD trials.","DEXTENZA sales fell 27.7% to $10.6M due to pricing strategy, MIPS inclusion; quarterly sales expected to rise for rest of 2025.","SOL-1 (Phase 3 wet AMD) topline data on track for 1Q 2026; FDA accepted SPA amendment allowing re-dosing at Weeks 52 and 76.","SOL-R enrollment strong after target cut to ~555 subjects; remains 90% powered for non-inferiority; expedited NDA submission possible.","Positive FDA feedback on potential AXPAXLI registrational trial in NPDR; company planning next steps in NPDR and DME."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":10698000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1937930532.7830918,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172221,"accession_number":"0001104659-25-019462","cik":1393434,"company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ocular Therapeutix reports FY2024 revenue $63.7M, net loss $(193.5)M; updates AXPAXLI registrational program","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $17.1M (+15.4% YoY); FY2024 revenue $63.7M (+9.0% YoY). Net loss $(193.5)M for FY2024 vs $(80.7)M in FY2023.","Cash balance $392.1M as of Dec 31, 2024; expected to fund operations into 2028; no plans to raise additional capital in 2025.","SOL-1 Phase 3 wet AMD trial amended to include re-dosing at Weeks 52 and 76; Week 36 primary endpoint data expected in 1Q 2026.","SOL-R trial size reduced from 825 to 555 subjects due to re-dosing inclusion in SOL-1; non-inferiority margin -4.5 letters BCVA vs aflibercept.","FDA feedback on AXPAXLI clinical trial design for NPDR and DME anticipated in 1H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1937930532.7830918,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172220,"accession_number":"0001104659-25-013473","cik":1393434,"company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CEO Dugel receives new compensation package with $819,200 salary, performance stock awards","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary raised to $819,200 annually; bonus target at 75% of salary; $368,100 2024 bonus plus $500,000 special one-time bonus.","Time-Based RSU Award: 1,250,000 shares vesting over three years.","Performance Awards: PSU up to 1,500,000 shares and Performance Option for 2,750,000 shares at $7.44 strike, tied to stock price hurdles from $15 to $30.","Performance awards contingent on stockholder approval for 2021 Plan increase; no annual equity grant for 2026.","Equity awards designed to align with long-term stockholder value; service-vesting through third anniversary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1937930532.7830918,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189201,"accession_number":"0001104659-24-118284","cik":1393434,"company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ocular Therapeutix Q3 net loss $36.5M; SOL-1 topline data expected Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $36.5M ($0.22 diluted EPS) vs $0.5M loss in Q3 2023; R&D spend jumped to $37.1M.","Total net revenue $15.4M (+2.3% YoY); DEXTENZA full-year 2024 revenue guided $62-67M.","Cash $427.2M as of Sep 30, 2024, expected to fund operations into 2028.","SOL-1 fully randomized by YE 2024 (accelerated); topline data now expected Q4 2025.","SOL-R trial open for direct enrollment after FDA Type C response; NDA support confirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":46641000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1937930532.7830918,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189200,"accession_number":"0001104659-24-107348","cik":1393434,"company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","form_type":"8-K","filed_at":"2024-10-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ocular Therapeutix increases inducement share reserve to 6.054M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board amended 2019 Inducement Stock Incentive Plan on Oct 4, 2024.","Share reserve increased from 4.804M to 6.054M shares, a net addition of 1.25M shares.","Plan permits equity awards to new employees as inducement for employment.","All other terms of the plan remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1937930532.7830918,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205699,"accession_number":"0001104659-24-096021","cik":1393434,"company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Ocular Therapeutix appoints Donald Notman as COO, retains CFO role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Donald Notman, age 65, appointed COO on August 29, 2024; continues as CFO and principal financial and accounting officer.","Notman has served as CFO since September 2017; prior roles include CFO of Thrasos Therapeutics and Managing Director at Leerink Swann.","No arrangements or family relationships with other directors/officers; no related party transactions under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1937930532.7830918,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205698,"accession_number":"0001104659-24-086535","cik":1393434,"company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ocular Therapeutix Q2 net loss $(43.8)M; AXPAXLI SOL-R accepted as pivotal trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $(43.8)M ($(0.26)/share) vs $(20.7)M ($(0.26)/share) in Q2 2023; revenue $16.4M (+8.3% YoY).","Cash $459.7M as of June 30, 2024; expected to fund operations into 2028.","FDA confirmed SOL-R repeat dosing study (Phase 3 wet AMD) is appropriate as second registrational trial; ~825 subjects to be randomized.","SOL-1 enrollment accelerating: 151 subjects enrolled as of June 7, 2024, 60 active sites.","HELIOS Phase 1 NPDR data showed DRSS improvement; no intraocular inflammation; presented at ASRS."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":31215000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1937930532.7830918,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222633,"accession_number":"0001104659-24-071530","cik":1393434,"company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Ocular Therapeutix shareholders approve doubling authorized shares to 400M and increasing equity plan by 7M shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved amendment to increase authorized common stock from 200M to 400M shares.","Stockholders approved Amendment No. 3 to 2021 Stock Incentive Plan, adding 7M shares for issuance.","Elected Adrienne L. Graves, Ph.D. and Charles Warden as Class I directors for term ending 2027.","Ratified PricewaterhouseCoopers LLP as independent auditor for FY 2024; votes: 119.6M for, 0.86M against.","Non-binding advisory vote on executive compensation passed with 76.3M for, 9.3M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1937930532.7830918,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222632,"accession_number":"0001104659-24-067544","cik":1393434,"company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Ocular Therapeutix cuts 13% of workforce, 37 jobs, to prioritize AXPAXLI","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved reduction in force of 37 employees (~13% of workforce), mainly in R&D and technical operations.","Action taken to focus resources on AXPAXLI (axitinib intravitreal implant) for wet AMD clinical development.","Expects total restructuring costs of $1.0 to $2.0 million for severance and related costs in Q2/Q3 2024.","Reduction expected to be substantially completed in Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1937930532.7830918,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222631,"accession_number":"0001104659-24-058003","cik":1393434,"company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ocular Therapeutix Q1 net loss $64.8M ($0.49/sh); revenue $14.8M up 10.4% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $64.8M ($0.49/sh) vs $30.3M loss ($0.39/sh) in Q1 2023; includes $28M non-cash loss on debt extinguishment.","Total net revenue $14.8M, up 10.4% YoY, driven by DEXTENZA product sales.","Cash and equivalents $482.9M; Feb 2024 private placement raised $325M; cash runway expected into 2028.","Phase 3 SOL-1 wet AMD trial randomization started April 2024; site activation progressing under FDA SPA.","Pravin Dugel appointed Exec Chairman, President & CEO; Investor Day set for June 13, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":14774000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1937930532.7830918,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222630,"accession_number":"0001104659-24-048850","cik":1393434,"company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","form_type":"8-K","filed_at":"2024-04-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ocular Therapeutix appoints Pravin Dugel as CEO, Nadia Waheed as CMO; stock plan increased","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pravin U. Dugel appointed President and CEO, effective April 14, 2024; he remains Executive Chairman.","Prior CEO Antony C. Mattessich resigned; severance includes 24 months base salary and 24-month equity acceleration.","Nadia Waheed appointed Chief Medical Officer effective May 20, 2024, replacing Rabia Gurses Ozden.","2019 Inducement Stock Incentive Plan amended to increase shares from 3,804,000 to 4,804,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1937930532.7830918,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242157,"accession_number":"0001104659-24-041224","cik":1393434,"company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ocular Therapeutix eliminates 50% service requirement in Dr. Kaiser's employment agreement","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["On March 28, 2024, Ocular Therapeutix modified the employment agreement of Medical Director Peter Kaiser, M.D.","The modification eliminated the 50% service requirement that required Dr. Kaiser to devote at least half his time to the company.","No other changes to the agreement or its terms were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1937930532.7830918,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242156,"accession_number":"0001104659-24-032974","cik":1393434,"company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ocular Therapeutix Q4 net loss $29.2M, revenue $14.8M; cash $195.8M plus $325M PIPE","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $29.2M ($0.35 loss per share); revenue $14.8M, up 5% YoY.","Full year 2023 net loss $80.7M ($1.01 loss per share); revenue $58.4M, up 13.4%.","Cash $195.8M at year-end; Feb 2024 PIPE added $325M gross proceeds, funding into at least 2028.","Appointed Pravin Dugel as Executive Chairman and three key retinal care leaders.","Phase 3 AXPAXLI SOL-1 screening underway; topline data for diabetic retinopathy and PAXTRAVA glaucoma expected Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1937930532.7830918,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242155,"accession_number":"0001104659-24-026324","cik":1393434,"company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["1.01","2.02","3.02","5.02","8.01","9.01"],"status":"ready","headline":"Ocular Therapeutix raises $325M in private placement; appoints Pravin Dugel as Executive Chairman","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered securities purchase agreement for 32.4M shares at $7.52/share and pre-funded warrants for 10.8M shares at $7.519/warrant, gross proceeds ~$325M.","Preliminary unaudited cash $195.8M as of Dec 31, 2023; preliminary FY2023 net product revenue ~$57.9M.","Pravin Dugel appointed Executive Chairman, effective Feb 21, 2024; receives $540K base salary, equity awards (1.28M options, 855K RSUs).","CEO Antony Mattessich's employment agreement amended to improve severance benefits; Lead Independent Director Charles Warden appointed.","Proceeds to accelerate AXPAXLI clinical development for wet AMD, including ongoing SOL-1 and planned SOL-2 Phase 3 trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1937930532.7830918,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242154,"accession_number":"0001104659-24-006490","cik":1393434,"company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","form_type":"8-K","filed_at":"2024-01-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ocular Therapeutix obtains FDA SPA modification for pivotal Phase 3 AXPAXLI wet AMD trial","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed to SPA modification for SOL trial evaluating AXPAXLI (axitinib intravitreal implant) for wet AMD.","Modified protocol allows enrollment of treatment-naïve subjects with visual acuity of 20/80 or better at screening.","Eligible participants must gain ≥10 ETDRS letters or achieve 20/20 vision at Day 1 after two aflibercept injections.","Trial will evaluate a single 450 µg implant of a more soluble form of axitinib for improved drug release.","Optimized implant designed to synchronize axitinib depletion with hydrogel bioresorption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1937930532.7830918,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}